. 2021 Jan 16;13(1):248. doi: 10.3390/nu13010248

Table 4.

Objective sleep outcomes for the placebo, DHA-rich, and EPA-rich treatment groups. Post-dose estimated marginal means and standard error (SE) are presented with F and p values of the main effects from the linear mixed models.

Variable	Treatment		Post-Dose		Main Effects
Variable	Treatment	n	Mean	SE		F	p
Latency (minutes)	Placebo	74	4.31 ^a	0.21	Treatment	3.68	0.026
	DHA-rich		3.76 ^a	0.26
	EPA-rich		3.98	0.27	Treatment × Night	2.28	0.009
Efficiency (%)	Placebo	72	90.30 ^a,T	0.50	Treatment	3.68	0.030
	DHA-rich		92.02 ^a	0.49
	EPA-rich		91.85 ^T	0.57	Treatment × Night	1.47	0.138
Total Minutes in bed (minutes)	Placebo	74	484.51	8.13	Treatment	3.29	0.039
	DHA-rich		494.85 ^b	6.63
	EPA-rich		467.10 ^b	8.55	Treatment × Night	0.851	0.598
Total Sleep Time (Minutes)	Placebo	73	437.91	7.56	Treatment	4.06	0.018
	DHA-rich		455.17 ^b	6.18
	EPA-rich		427.28 ^b	8.08	Treatment × Night	1.20	0.281
Wake after Sleep Onset (minutes)	Placebo	72	42.02	2.42	Treatment	2.55	0.084
	DHA-rich		35.84	2.14
	EPA-rich		34.77	2.74	Treatment × Night	1.29	0.225
Number of Awakenings	Placebo	74	17.50	0.99	Treatment	0.813	0.446
	DHA-rich		15.87	0.88
	EPA-rich		16.20	1.08	Treatment × Night	1.19	0.289
Average Awakening Length (minutes)	Placebo	74	2.44	0.11	Treatment	0.576	0.564
	DHA-rich		2.29	0.09
	EPA-rich		2.38	0.12	Treatment × Night	1.50	0.126
Sleep Fragmentation Index	Placebo	74	22.89	1.28	Treatment	0.802	0.451
	DHA-rich		20.80	1.11
	EPA-rich		22.22	1.38	Treatment × Night	1.90	0.036

^a = significant difference between active and placebo groups, p < 0.050; ^b = significant difference between the active treatment groups, p < 0.050; ^T = trend towards a significant difference between active and placebo groups, p < 0.100.